Locations:
Search IconSearch
August 3, 2015/Neurosciences/Case Study

In Epilepsy, Sleep Apnea Can Be at Play Even When You Least Expect It

Case shows importance of sleep apnea screening in all epileptic patients

Case-Study-690×380

By Nancy Foldvary-Schaefer, DO, MS

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Presentation

A 25-year-old man presented to Cleveland Clinic’s Epilepsy Center in 2002 with epileptic seizures occurring as frequently as once a day and convulsions occurring about once a week. Diagnosed with epilepsy at age 15, he had never been able to work outside the home or drive a car.

The patient was evaluated at Cleveland Clinic for surgical therapy, as his seizures were not controlled by anti-epileptic medications (oxcarbazepine and levetiracetam, prescribed at another institution). Because we were unable to localize his seizures, he was not a candidate for resection. He did receive a vagus nerve stimulator (VNS), which also proved ineffective in controlling his seizures.

Evaluation

The patient did not display the classic symptoms of sleep apnea. He was not greatly overweight. He had mild, intermittent snoring, but his wife did not observe cessation of breathing during the night.

Nevertheless, we decided to conduct a sleep study because sleep apnea has been associated with worsening epileptic seizures. In the laboratory at the Cleveland Clinic Sleep Disorders Center, he was observed to have 17 episodes of breathing cessation per hour of sleep; 15 episodes is considered to be moderate sleep apnea, and 30 is classified as severe. The medical literature indicates that a frequency of 15 episodes per hour increases the risk of a variety of cardiovascular events, including heart attack and stroke. In addition, his oxygen saturation level dropped to 67 percent during the study, which is considered significant desaturation.

Advertisement

Treatment

The patient was placed on continuous positive airway pressure (CPAP) therapy at a pressure level of 10 cm of water, ensuring that his apnea episodes would occur fewer than five times per hour and his oxygen saturation level would exceed 90 percent. He continued medical therapy with anti-seizure medications, which were adjusted over time as new drugs, with fewer side effects, became available. (He now takes topiramate and lamotrigine.)

Outcome

After beginning CPAP therapy, the patient gradually experienced fewer and fewer seizures. Within about two months they had stopped altogether.

During a 10-year follow-up period, he remained seizure-free. Initially, we weren’t sure what role each of the treatments (CPAP therapy, VNS, medications) played in his improvement. But when the VNS failed twice — the second time permanently — and the seizures did not recur, we concluded that the CPAP therapy had the most impact.

Eight years after beginning CPAP therapy, he returned to the Sleep Disorders Center complaining of recurrent daytime sleepiness, but not seizures. In the sleep laboratory we determined that he required a higher pressure from the CPAP machine (a common development for patients who have been on CPAP therapy for several years). After the pressure was increased, his sleepiness resolved.

This father of two can now drive a car, and he works full-time as a quality technician in the auto industry.

Discussion: More sleep apnea screening needed in epileptic patients

The association between obstructive sleep apnea and epilepsy is fairly well recognized. Our group recently published a study demonstrating the benefit of CPAP therapy in reducing seizures among patients with epilepsy.

Advertisement

Despite a growing body of evidence pointing to sleep apnea as an activator of seizures, few epilepsy providers refer their patients for sleep studies. Most patients who come to us have never had a discussion with their doctors about their sleep. We believe that every patient with epilepsy, and especially those whose seizures are poorly controlled, should be screened for sleep apnea. This is one of the ways we can greatly enhance the quality of life for these patients.

Dr. Foldvary-Schaefer is Director of Cleveland Clinic’s Sleep Disorders Center and a staff physician in the Epilepsy Center.

Advertisement

Related Articles

16-NEU-2800-Kubu-101058161-650×450
What Do Patients Want from DBS for Parkinson’s Disease?

New study advances understanding of patient-defined goals

photo of a man sleeping at a desk, with a podcast icon overlay
March 15, 2024/Neurosciences/Podcast
Diagnosis and Management of Idiopathic Hypersomnia (Podcast)

Testing options and therapies are expanding for this poorly understood sleep disorder

illustration of an alzheimer brain and a packet of sildenafil pills
March 11, 2024/Neurosciences/Research
Sildenafil as an Alzheimer’s Candidate Drug: Further Support From Insurance Database and Mechanistic Studies

Real-world claims data and tissue culture studies set the stage for randomized clinical testing

brain scan showing perimesencephalic subarachnoid hemorrhage
Study Supports Less-Strict Monitoring for Nonaneurysmal Perimesencephalic SAH Without Hydrocephalus

Digital subtraction angiography remains central to assessment of ‘benign’ PMSAH

illustrated brain with the letters "AI" on a computer circuit board
As AI Tools Emerge, Be Proactive and Engaged to Shape Their Development

Cleveland Clinic neuromuscular specialist shares insights on AI in his field and beyond

histology image of a gray matter lesion in a multiple sclerosis brain
Study Suggests Protective Role for Microglia at Borders of Gray Matter Lesions in Progressive MS

Findings challenge dogma that microglia are exclusively destructive regardless of location in brain

series of digital-looking brain icons with a podcast button overlay on top
March 1, 2024/Neurosciences/Podcast
Harnessing the Power of AI in Medicine (Podcast)

Neurology is especially well positioned for opportunities to enhance clinical care and medical training

illustration of a neuron affected by multiple sclerosis
Clinical Trials in Progressive MS: An Assessment of Advances and Remaining Challenges

New review distills insights from studies over the past decade

Ad